Health Care Equipment & Services

CEO‑led RSU grant boosts Myomo’s investor sentiment, signals management confidence, and aligns executive interests with long‑term shareholder value.

Bioventus insider buying signals confidence in bone‑healing trials and future FDA approval, offering investors a bullish outlook on a niche biotech player.

HeartFlow CEO sells shares in a rule‑based plan; the move shows confidence in long‑term value, supports strong price momentum, and signals potential liquidity for growth.

Insider sale of 750 Veeva shares shows routine liquidity, not distress, yet signals volatility—watch executive buys for clues to a potential rebound.

SiNtx Technologies insider buying signals confidence in its silicon‑nitride devices, backed by solid clinical safety data and an upcoming FDA PMA, offering investors a potential upside.

Lucid Diagnostics insider stake rise fuels optimism as breakthrough esophageal brush‑biopsy tech shows 92% sensitivity, 88% specificity, and strong FDA support, hinting at future growth.

Insider buys 3,775 Elevance Health shares at zero cost, signaling board confidence. Learn how this aligns with tech‑driven value‑based care, Medicare expansion, and market gains.

Insider trades at Sonida Senior Living reveal routine liquidity moves while hinting at strategic expansions into New Zealand and Asia‑Pacific, impacting debt‑equity and future growth.

Explore how Sophia Genetics’ CEO insider sales—executed under a Rule 10b‑5(1) plan—reflect tax‑driven liquidity, market stability, and growth prospects in cloud‑based genomic analytics.

Omada Health insider sale: CEO Wei‑Li Shao sells 2,829 shares as the price dips below $12, reflecting cautious liquidity management rather than a confidence drop.